Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

Christoph D. Spinner; Robert Gottlieb; Gerard J. Criner; José Ramón Arribas; Anna Maria Cattelan; Álex Soriano; Onyema Ogbuagu; Prashant Malhotra; Kathleen M. Mullane; Antonella Castagna; Louis Yi Ann Chai; Meta Roestenberg; Owen Tak Yin Tsang; Enos Bernasconi; Paul Le Turnier; Shan‐Chwen Chang; Devi SenGupta; Robert H. Hyland; Anu Osinusi; Huyen Cao; Christiana Blair; Hongyuan Wang; Anuj Gaggar; Diana M. Brainard; Mark McPhail; Sanjay Bhagani; Mi Young Ahn; Arun J. Sanyal; Gregory Huhn; Francisco M. Marty

doi:10.1001/jama.2020.16349

Abstract

ClinicalTrials.gov Identifier: NCT04292730.

Keywords

MedicineOdds ratioRandomized controlled trialPneumoniaInternal medicinePlaceboClinical trialSeverity of illnessCoronavirus disease 2019 (COVID-19)OddsLogistic regressionDiseasePathologyInfectious disease (medical specialty)

Affiliated Institutions

Related Publications

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

André C. Kalil , Thomas F. Patterson , Aneesh K. Mehta +57 more

Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably amon...

2020 New England Journal of Medicine 1863 citations

Remdesivir for the Treatment of Covid-19 — Preliminary Report

James McMahon , Andrew Udy , Anton Y. Peleg

BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious.\nMETHOD...

2020 New England Journal of Medicine 1453 citations

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Mayla Gabriela Silva Borba , Fernando Val , Vanderson de Souza Sampaio +25 more

ClinicalTrials.gov Identifier: NCT04323527.

2020 JAMA Network Open 960 citations

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Li Tan , Qi Wang , Duanyang Zhang +5 more

Background: Coronavirus disease-2019 (COVID-19) is a rapidly escalating epidemic caused by SARS-CoV-2. Identification of a simple and effective indicator to assess disease sever...

2020 Signal Transduction and Targeted Therapy 1583 citations

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Peter Horby , Marion Mafham , Louise Linsell +26 more

BACKGROUND: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrol...

2020 New England Journal of Medicine 1266 citations

Publication Info

Year: 2020
Type: article
Volume: 324
Issue: 11
Pages: 1048-1048
Citations: 1250
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1250

OpenAlex

Cite This

APA Style

                            
                                
                                    Christoph D. Spinner, 
                                
                                    Robert Gottlieb, 
                                
                                    Gerard J. Criner
                                
                                et al.
                            
                            (2020). 
                            Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. 
                            JAMA
                            , 324
                            (11)
                            , 1048-1048.
                            https://doi.org/10.1001/jama.2020.16349
                        

Identifiers

DOI: 10.1001/jama.2020.16349